MedTrace Logo

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

NCT03269136 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2025-03-18

Study results available
· View outcomes & findings →

Summary

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Conditions

Interventions

DRUG

PF-06863135 monotherapy IV or SC

PF-06863135 will be administered intravenously or subcutaneously.

DRUG

PF-06863135 + dexamethasone

PF-06863135 will be administered intravenously or subcutaneously and dexamethasone orally.

DRUG

PF-06863135 + lenalidomide

PF-06863135 will be administered intravenously or subcutaneously and lenalidomide orally

DRUG

PF-06863135 + pomalidomide

PF-06863135 will be administered intravenously or subcutaneously and pomalidomide orally

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-29
Primary Completion
2024-01-19
Completion
2024-01-19
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03269136 on ClinicalTrials.gov